SCHEMBL21725628

SCHEMBL21725628

CC(C)N1CCc2cccc(C(F)(F)F)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.39
AADAT Q8N5Z0 1/20 0.38
NOTUM Q6P988 1/20 0.36
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACACB O00763 1/20 0.34
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34
DRD5 P21918 1/20 0.34
DRD3 P35462 1/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725631 0.85 P2RX7 (0.35) P2RX7AADATNOTUMALDH1A1PKM
SCHEMBL23717652 0.83 P2RX7 (0.42) P2RX7AADATNOTUMALDH1A1PKM
SCHEMBL23717842 0.80 C5AR1 (0.33) P2RX7ACACBHTR2CHTR2BSLC6A2
SCHEMBL21725629 0.78 AADAT (0.40) P2RX7AADATNOTUMALDH1A1PKM
SCHEMBL21725590 0.78 DRD2 (0.37) AADATNOTUMMAOAMAOBDRD2
SCHEMBL13180800 0.76 ALOX12 (0.46) NOTUMMAOAMAOBDRD2DRD1
SCHEMBL12905310 0.75 AADAT (0.38) AADATNOTUMALDH1A1PKMHTT
SCHEMBL18329551 0.75 NOTUM (0.53) P2RX7NOTUMMAOAMAOBDRD2
SCHEMBL18329553 0.75 HTR2C (0.38) NOTUMMAOAMAOBDRD2DRD1
SCHEMBL20345679 0.75 MAOA (0.37) NOTUMMAOAMAOBDRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R P2RX7 628/4885AADAT 344/4885NOTUM 4477/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R P2RX7 628/4885AADAT 344/4885NOTUM 4477/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R P2RX7 628/4885AADAT 344/4885NOTUM 4477/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R P2RX7 628/4885AADAT 344/4885NOTUM 4477/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R P2RX7 628/4885AADAT 344/4885NOTUM 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.